详情页 - 四川省肿瘤医院知识库

资源类型：

文章类型：

作者：

Tan, Fenlai[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] * ; Gu, Aiqin[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Zhang, Yiping[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Jiao, Shun Chang[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Wang, Chang-Li[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; He, Jintao[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16]

; Jia, Xueke[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Zhang, Li[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16]

; Peng, Jiewen[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Wu, Meina[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Ying, Kejing[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Wang, Junye[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Ma, Kewei[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Zhang, Shucai[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; You, Changxuan[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Ding, Lieming[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Wang, Yinxiang[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Shen, Haijiao[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Wan, Jiang[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Sun, Yan[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ;

机构： [1]Zhejiang Beta Pharma Inc, Hangzhou, Zhejiang, Peoples R China [2]Shandong Prov Chest Hosp, Shanghai, Peoples R China [3]Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China [4]Gen Hosp PLA, Beijing, Peoples R China [5]Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China [6]Sichuan Canc Hosp & Inst, Chengdu, Peoples R China [7]Baoding Hengxing Med Integrat Hosp, Baoding, Peoples R China [8]Perking Union Med Hosp, Beijing, Peoples R China [9]Zhongshan Peoples Hosp, Zhongshan, Peoples R China [10]Beijing Canc Hosp, Beijing, Peoples R China [11]Sir Run Run Shaw Hosp, Hangzhou, Zhejiang, Peoples R China [12]Sun Yat Sen Univ, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China [13]Jilin Univ, Bethune Hosp 1, Changchun 130023, Peoples R China [14]Beijing Chest Hosp, Beijing, Peoples R China [15]China Nanfang Hosp, Guangzhou, Guangdong, Peoples R China [16]Chinese Acad Med Sci, Canc Inst & Hosp, Beijing 100730, Peoples R China

出处：

DOI：

ISSN：

语种：

WOS：

中科院(CAS)分区：

出版当年[2013]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

JCR分区：

出版当年[2013]版：

Q1 ONCOLOGY

最新[2023]版：

Q1 ONCOLOGY

第一作者：

第一作者机构： [1]Zhejiang Beta Pharma Inc, Hangzhou, Zhejiang, Peoples R China [2]Shandong Prov Chest Hosp, Shanghai, Peoples R China [3]Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China [4]Gen Hosp PLA, Beijing, Peoples R China [5]Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China [6]Sichuan Canc Hosp & Inst, Chengdu, Peoples R China [7]Baoding Hengxing Med Integrat Hosp, Baoding, Peoples R China [8]Perking Union Med Hosp, Beijing, Peoples R China [9]Zhongshan Peoples Hosp, Zhongshan, Peoples R China [10]Beijing Canc Hosp, Beijing, Peoples R China [11]Sir Run Run Shaw Hosp, Hangzhou, Zhejiang, Peoples R China [12]Sun Yat Sen Univ, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China [13]Jilin Univ, Bethune Hosp 1, Changchun 130023, Peoples R China [14]Beijing Chest Hosp, Beijing, Peoples R China [15]China Nanfang Hosp, Guangzhou, Guangdong, Peoples R China [16]Chinese Acad Med Sci, Canc Inst & Hosp, Beijing 100730, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

Safety and efficacy results of a phase IV, open-label, multicenter, safety-monitoring study of icotinib in treating advanced non-small cell lung cancer (NSCLC): ISAFE study

文献详情